To recover your password please fill in your email address
Please fill in below form to create an account with us
The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will aim to assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give daily temozolomide as soon as possible after surgery prior to chemoradiotherapy (CRT) and QUESTION 2: whether to give 6 cycles of temozolomide after CRT, or continue monthly treatment until disease progression.
See full ANZCTR details for MAGMA >
|
Trial Summary: |
A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma. Initial questions of interest are: QUESTION 1: whether to give metronomic temozolomide as soon as possible following surgery prior to chemoradiotherapy; and QUESTION 2: whether to give a plan for 6 cycles of standard schedule adjuvant temozolomide chemotherapy (5/28 day cycles) after chemoradiotherapy, or continue temozolomide until progression. |
|
Supported by: |
Australian Brain Cancer Mission, including Cancer Australia, Carries Beanies for Brain Cancer, and the Mark Hughes Foundation, through the MRFF. |
|
Eligibility: |
Adults, aged 18 years and older, with newly diagnosed histologically confirmed grade IV malignant glioblastoma. |
|
Registration ID: |
ACTRN12620000048987 |
|
Participation: |
Australia |
|
Australian Lead Group: |
COGNO |
|
Status: |
Recruiting |
|
Activation Date: |
09/2020 |
|
Chairs: |
A/Prof Craig Gedye
|
|
Contact: |